INT149295

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.13
First Reported 2008
Last Reported 2011
Negated 2
Speculated 0
Reported most in Body
Documents 10
Total Number 10
Disease Relevance 4.26
Pain Relevance 1.22

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (NOTCH1) nucleoplasm (NOTCH1) extracellular region (NOTCH1)
Golgi apparatus (NOTCH1) plasma membrane (NOTCH1) nucleus (NOTCH1)
Anatomy Link Frequency
Notch 3
cleavage 2
plasma 1
lung 1
NOTCH1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Pain 7 98.64 Very High Very High Very High
corticosteroid 36 98.52 Very High Very High Very High
cINOD 18 97.00 Very High Very High Very High
Abeta 9 86.16 High High
headache 5 34.36 Quite Low
tolerance 1 30.72 Quite Low
Osteoarthritis 94 28.08 Quite Low
cytokine 16 22.80 Low Low
Inflammation 44 5.00 Very Low Very Low Very Low
metalloproteinase 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Adult Respiratory Distress Syndrome 63 100.00 Very High Very High Very High
Influenza Virus Infection 98 99.64 Very High Very High Very High
Alzheimer's Dementia 6 99.36 Very High Very High Very High
Pain 7 98.64 Very High Very High Very High
Disease 72 98.36 Very High Very High Very High
Apoptosis 18 97.00 Very High Very High Very High
INFLAMMATION 53 96.72 Very High Very High Very High
Leukemia 8 96.60 Very High Very High Very High
Disseminated Intravascular Coagulation 6 94.88 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 5 90.64 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
0.5 (0.14 ng/ml) to 11.45 nmol/ml (3.19 ng/ml) for clades 2 and 3 and 0.09 (0.03) to 2.3 (0.8) nmol/ml (ng/ml) for clade 1.[15], [16] These values are many fold lower than OC plasma concentrations in mild influenza but the clinical efficacy of oseltamivir alone in H5N1 is limited.[1], [2], [3] Reasons for this may include irreversible lung damage at presentation, immune mediated pathology, development of H5N1 resistance to OC, reduced OC tissue distribution/penetration and low oseltamivir absorption in severely ill patients secondary to possible gastric paresis, small bowel ileus or diarrhoea.[5], [17] Better insight into the pharmacokinetics and pharmacodynamics of OC in patients with H5N1 and other forms of severe influenza is urgently needed.
Regulation (efficacy) of H5N1 in lung associated with ileus, diarrhoea, paresis and influenza virus infection
1) Confidence 0.13 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2565445 Disease Relevance 0.68 Pain Relevance 0
His H5N1 viral titre in bronchial-alveolar lavage fluid declined substantially and was undetectable for the next 3 consecutive days after receipt of the third convalescent plasma dose.
Regulation (undetectable) of H5N1 in plasma
2) Confidence 0.08 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2515635 Disease Relevance 0.81 Pain Relevance 0
For severely ill Chinese H5N1 patients with ARDS or multiorgan failure, management has focused on appropriate mechanical ventilation, correction of hypoxemia, fluid management, and treatment of other complications such as DIC.
Regulation (focused) of H5N1 associated with disseminated intravascular coagulation and adult respiratory distress syndrome
3) Confidence 0.07 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2515635 Disease Relevance 0.60 Pain Relevance 0.21
However, we cannot conclude that corticosteroid therapy resulted in survival and such treatment has not been shown to be effective in H5N1 patients [2].
Regulation (effective) of H5N1 associated with corticosteroid
4) Confidence 0.07 Published 2008 Journal PLoS ONE Section Body Doc Link PMC2515635 Disease Relevance 0.63 Pain Relevance 0.36
Interestingly, some non-steroidal anti-inflammatory drugs (NSAIDs) and other small organic molecules have been found to modulate gamma-secretase and to selectively reduce beta-amyloid(1-42) (Abeta42) levels without affecting Notch cleavage.
Neg (without) Regulation (affecting) of Notch in cleavage associated with inflammation, alzheimer's dementia and cinod
5) Confidence 0.06 Published 2008 Journal Curr Top Med Chem Section Abstract Doc Link 18220933 Disease Relevance 0.90 Pain Relevance 0.55
The Notch signalling pathway regulates diverse cellular processes, including proliferation, differentiation, and apoptosis [36], and was reported to contribute to the regulation of L-PGDS expression [37].
Regulation (regulates) of Notch in Notch associated with apoptosis
6) Confidence 0.04 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656251 Disease Relevance 0.10 Pain Relevance 0
-secretase inhibitor, which blocks cleavage of the intracellular domain of all Notch proteins, and is widely used to evaluate the effect of Notch inhibition [36].
Regulation (effect) of Notch in cleavage
7) Confidence 0.04 Published 2008 Journal Arthritis Res Ther Section Body Doc Link PMC2656251 Disease Relevance 0.09 Pain Relevance 0
In addition to the classical Notch pathway, other routes may be used to modulate the carcinogenic potential of elevated Notch signaling in CSCs.
Regulation (modulate) of Notch in Notch
8) Confidence 0.04 Published 2011 Journal Journal of Oncology Section Body Doc Link PMC2958340 Disease Relevance 0.27 Pain Relevance 0
42 production by a factor of 6, but had no significant effect on Notch processing [52].
Neg (no) Regulation (effect) of Notch in Notch
9) Confidence 0.03 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2405781 Disease Relevance 0 Pain Relevance 0
g HA dose of the split-virus H5N1 vaccine adjuvanted with AS03 was compared with the licensed seasonal influenza vaccine Fluarix™ in healthy adults aged 18 years and above.51 Significantly more participants in the AS03-H5N1 vaccine group reported general or local adverse events (84·3% versus 40·2% of subjects 18–60 years and 69·4% versus 34·1% of subjects >60 years, receiving adjuvanted H5N1 antigen and control, respectively).51 Injection-site pain was the most common symptom in both treatment groups within the 7–day post-vaccination period (after first dose: 87·6% versus 64·5% of subjects 18–60 years and 57·8% versus 27·1% in subjects >60 years receiving adjuvanted recombinant H5N1 and Fluarix™, respectively, and after a second dose: 75·5% versus 15·7% of subjects 18–60 years and 50·4% versus 6·1% in subjects >60 years receiving adjuvanted recombinant H5N1 and placebo, respectively).
Regulation (control) of H5N1 associated with pain and influenza virus infection
10) Confidence 0.01 Published 2008 Journal Influenza and Other Respiratory Viruses Section Body Doc Link PMC2710798 Disease Relevance 0.19 Pain Relevance 0.10

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox